Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health
Spectra Intelligence
May 25, 2011 72 Pages - SKU: SPIN6384091
|
|
Countries covered: Global
The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.
In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health (2nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.
The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.
Key findings of the report include
- The worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.
- Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.
- Currently, there are over 40 pipeline candidates for female and male contraception.
- The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.
- Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.
- Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.
- The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.
Questions answered by this report include:
- Which contraceptives and infertility drugs are the current and potential future market leaders
- What impact new drug approvals will have on the reproductive medicine drug market
- Which premarket drugs are identified as high-value products
- Which companies are developing hormonal contraceptives and infertility drugs
- Sales predictions to 2018 for leading contraceptives and infertility drugs
- How will newcomers affect the product positioning of market leaders
- What are niche market opportunities in reproductive medicine
- What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies
- How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders
- Which molecules and compounds are main R&D clusters in reproductive medicine
|
Additional InformationResearch Methodology
The contents of this URCH Publishing report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:
- Company information
- Scientific periodicals
- Personal communication
- Product information
- Trade press articles
- Market analyst data
- News releases
- Public information datasets
- Internet-based research
- Conference proceedings
- Library research
- Medical/pharma associations
- Executive Summary
- Report Highlights
- Objectives of the Report
- 1. Contraception and Infertility: Market Snapshot
- Market data synopsis - contraception and infertility
- 1.1 Reproductive Health Market Overview
- 1.2 Market Analysis for Contraception and Infertility
- 1.2.1 Contraception
- 1.2.2 Infertility
- 2. Product Market for Hormonal Contraception
- 2.1 Contraceptive Formulations
- 2.2 Combined Estrogen-Progestogen Contraceptives
- 2.3 Progestogen-Only Contraceptives
- 2.4 Product Market for Hormonal Contraceptives
- 2.4.1 Bayer Healthcare Pharmaceuticals
- 2.4.1.1 Key Product and Portfolio Review
- 2.4.1.2 Pipeline Focus
- Contraceptive Patch
- Intrauterine device
- 2.4.1.3 Sales Estimates and Product Market Outlook
- 2.4.2 Johnson & Johnson
- 2.4.2.1 Key Product and Portfolio Review
- 2.4.2.2 Sales Forecasts and Product Market Outlook
- 2.4.3 Merck & Co
- 2.4.3.1 Key Product and Portfolio Review
- 2.4.3.2 Sales Estimates and Product Market Outlook
- 2.4.4 Pfizer
- 2.4.4.1 Key Product and Portfolio Review
- 2.4.4.2 Sales Estimates and Product Market Outlook
- 2.4.5 Teva Pharmaceutical Industries
- 2.4.5.1 Key Product and Portfolio Review
- 2.4.5.2 Pipeline Focus
- 2.4.5.3 Sales Estimates and Product Market Outlook
- Generics Focus - Watson Pharmaceuticals
2.5 Future Considerations and Outlook for the Contraceptive Product Market
- 3. Product Market for Infertility Drugs
- 3.1 Overview for Infertility Drugs
- 3.2 Pharmacotherapies for Infertility
- Mechanism of Action of Infertility Pharmacotherapeutics
- 3.3 Product Market for Infertility Drugs
- 3.3.1 AstraZeneca
- 3.3.1.1. Key Product Review
- 3.3.1.2 Sales Estimates and Product Market Outlook
- 3.3.2 Ferring
- 3.3.2.1 Key Product and Portfolio Review
- 3.3.2.2. Sales Estimates and Product Market Outlook
- 3.3.3 Merck & Co
- 3.3.3.1 Key Product and Portfolio Review
- 3.3.4 Merck Serono
- 3.3.4.1 Key Product and Portfolio Review
- 3.3.4.2 Sales Estimates and Product Market Outlook
- 3.4 Market Outlook for Infertility Pharmacotherapeutics
- 4. Research and Development in Reproductive Health
- 4.1 Female Oral Contraception
- 4.1.1 Transdermal/Transmucosal Contraceptives
- 4.1.2 Implantable/Injectable Contraceptives
- 4.2 Male Contraception
- 4.3 Contraception - Research and Development Overview
- 4.4 Infertility Drugs in Research and Development
- 4.4.1 Female Infertility
- 4.4.2 Male Infertility
- 6.3.2.1 Infertility - Research and Development Overview
- Reference Sources
- List of Tables
- Research Methodology
- Table 1.1 Estimated Global Sales (US$m) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
- Table 2.1 Selection of Hormonal Contraceptives Segmented by Formulation and Delivery Route, 2011
- Table 2.2 Bayer's Hormonal Contraceptive Product Portfolio, 2011
- Table 2.3 Bayer`s Pipeline Contraceptive Candidates, 2011
- Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Bayer's Leading Hormonal Contraceptive Products, 2011-2018
- Table 2.5 Johnson & Johnson`s Hormonal Contraceptive Product Portfolio, 2011
- Table 2.6 Estimated Sales (US$m) and Annual Growth (%) of Johnson & Johnson`s Leading Hormonal Contraceptive Products, 2011-2018
- Table 2.7 Merck & Co's Hormonal Contraceptive Product Portfolio, 2011
- Table 2.8 Estimated Sales (US$m) and Annual Growth (%) of Merck & Co's Leading Hormonal Contraceptive Products, 2011-2018
- Table 2.9 Pfizer`s Hormonal Contraceptive Product Portfolio, 2011
- Table 2.10 Estimated Sales (US$m) and Annual Growth (%) of Pfizer`s Leading Hormonal Contraceptive Products, 2011-2018
- Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011
- Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011 (continued)
- Table 2.12 Estimated Sales (US$m) and Annual Growth (%) of Teva`s Leading Hormonal
- Table 3.1 Pharmacotherapies for Infertility, 2011
- Table 3.2 Ferring`s Infertility Product Portfolio, 2011
- Table 3.3 Estimated Global Sales (US$m) and Annual Growth (%) of Ferring`s Infertility Products, 2011-2018
- Table 3.4 Merck & Co.`s Hormonal Infertility Product Portfolio, 2011
- Table 3.5 Estimated Global Sales (US$m) and Annual Growth (%) of Merck & Co.'s Hormonal Infertility Products, 2011-2018
- Table 3.6 Merck Serono`s Hormonal Infertility Product Portfolio, 2011
- Table 3.7 Estimated Global Sales (US$m) and Annual Growth (%) of Merck Serono`s Hormonal Infertility Products, 2011-2018
- Table 4.1 Female Oral Contraceptives in Development, 2011
- Table 4.1 Female Oral Contraceptives in Development, 2011 (continued)
- Table 4.2 Transdermal/Transmucosal Female Contraceptives in Development, 2011
- Table 4.3 Implantable/Injectable Female Contraceptives in Development, 2011
- Table 4.4 Male Contraceptives in Development, 2011
- Table 4.5 Drugs in Development for Female Infertility, 2011
- Table 4.6 Drugs in Development for Male Infertility, 2011
- List of Figures
- Figure 1.1 Estimated Sales (US$m) and Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
- Figure 1.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2011 & 2018
- Figure 2.1 Global Revenue Trends for Bayer's Leading Hormonal Contraceptive Products, 2005-2010
- Figure 2.2 Global Revenue Trends for Johnson & Johnson's Leading Hormonal Contraceptive Products, 2005-2010
- Figure 2.3 Global Revenue Trends for Merck & Co's Leading Hormonal Contraceptive Products, 2005-2010
- Figure 2.4 Global Product Sales for Pfizer's Hormonal Contraceptive Franchise, 2005-2010
- Figure 2.5 Global Sales Trends of Teva's Leading Hormonal Contraceptive Products, 2005-2010
- Figure 2.6 Leading Hormonal Contraceptive Products by Sales Revenue (US$m), 2011 (estimated)
- Figure 3.1 Global Sales Trends of Merck & Co.'s Leading Hormonal Infertility Products, 2005-2010
- Figure 3.2 Global Sales Trends of Merck Serono's Leading Hormonal Infertility Products,
- Figure 3.3 Leading Hormonal Infertility Products by Sales Revenue (US$m), 2011 (estimated)
More Global Reproductive Health Reports
Top 50 Contraception (Global) by
Plimsoll Publishing Ltd.
The Global Contraception Industry Report Plimsoll Publishing Ltd. This report is an in-depth financial evaluation of the Global Contraception Industry. Using the unique Plimsoll method of analysis, ...
The 2011-2016 World Outlook for Lambskin Condoms by
Icon Group International, Inc.
This econometric study covers the world outlook for lambskin condoms across more than 200 countries. For each year reported, estimates are given for the latent ...
Women's Health Review and Outlook 2011 by
PharmaLive Special Reports
The global women's health market, valued at $20 billion in 2009, is dominated by the United States. Hormonal contraceptives is one of the leading categories ...
Contraceptives by
Global Industry Analysts
This report analyzes the worldwide markets for Contraceptives in US$ Million by the following product segments: Oral Contraceptives, Condoms, Implants/ Injections, and Others. The report ...
Condoms by
Global Industry Analysts
This report analyzes the worldwide markets for Condoms in Million Units and US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, ...
See all reports like this >>
Share this report
Other tasks Related Markets Reproductive Health Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
